Email updates

Keep up to date with the latest news and content from Journal of Cardiovascular MR and BioMed Central.

This article is part of the supplement: Abstracts of the 2011 SCMR/Euro CMR Joint Scientific Sessions

Open Access Open Badges Poster presentation

Safety and efficacy of early atropine injection for dobutamine stress cardiac magnetic resonance: a single center experience

Vincent Woo1*, Stanley Lau2 and Gerald M Pohost3

  • * Corresponding author: Vincent Woo

Author Affiliations

1 Harbor-UCLA Medical Center, Torrance, CA, USA

2 University of Southern California, Los Angeles, CA, USA

3 Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

For all author emails, please log on.

Journal of Cardiovascular Magnetic Resonance 2011, 13(Suppl 1):P127  doi:10.1186/1532-429X-13-S1-P127

The electronic version of this article is the complete one and can be found online at:

Published:2 February 2011

© 2011 Woo et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Dobutamine is an effective pharmacologic stress agent commonly used in cardiac stress testing, but has several well documented adverse effects including serious arrhythmias and myocardial infarction. The most common dobutamine protocol is to infuse an increasing dose of 10 µg/kg followed by 20, 30, then 40 µg/kg until target HR is achieved. Atropine may be added after the 40 µg/kg infusion if target heart rate is not achieved. An alternative strategy for dobutamine infusion involves earlier atropine administration, i.e. infusion of atropine after the 10, 20, or 30 µg/kg doses of dobutamine. In the echocardiography literature this strategy has been shown to have a better safety profile while maintaining the ability to achieve target heart rate. Dobutamine stress CMR may benefit from adopting a similar protocol.


The objective of this study is to assess the safety and efficacy of the addition of early atropine injection to dobutamine for stress CMR.


This is a single center, retrospective study involving 168 patients undergoing early-atropine dobutamine stress CMR for the evaluation of chest pain. All patients underwent a hybrid stress CMR protocol with evaluation of wall motion, perfusion, and late gadolinium enhancement. Demographic and stress CMR data are gathered from an electronic medical records system. The stress CMR data that were collected included the doses of dobutamine and atropine administered, the time of atropine infusion, the heart rate and blood pressure responses, and the incidence of adverse effects. All data are entered into a Microsoft Excel spreadsheet, where statistical analyses were performed.


The mean age of the patients undergoing CMR was 70.8 ± 7.6 years, with 91 females and 77 males. 156 patients were Asian, 8 were Caucasian, and 3 were Hispanic. 128 patients had hypertension, 96 had hyperlipidemia, and 46 had diabetes. 53 patients had documented coronary artery disease. Patients received an average of 8.5 ± 4.8 mg of dobutamine and 0.26 ± 0.19mg of atropine during the examination. Of 168 patients, 158(94%) achieved target heart rate or85% of maximum predicted. In our population, 14 patients were positive for ischemia. Of 168 examinations, 167 were considered of diagnostic quality. Three patients were hypotensive during the examination, while 1 was hypertensive 3 reported chest pain, and 1 reported dizziness. Tables 1-3, figure 1.

Table 1. Patient demographics

Table 2. Hemodynamic response

Table 3. CMR results


The early-atropine, dobutamine stress CMR test can be performed with an excellent safety profile and a lower dose of stress agent compared with the standard late-atropine strategy.